-
Roth Capital Likes Ligand, But Valuation Renders Shares 'Increasingly Speculative'
Wednesday, August 8, 2018 - 1:42pm | 293Read More...Ligand Pharmaceuticals Inc. (NASDAQ: LGND) beat top-line, bottom-line and royalties estimates in its second-quarter report, and it boosted annual guidance in the process. But one analyst sees limited opportunity for near-term growth. The Rating Roth Capital Partners analyst Scott Henry downgraded...
-
Roth Capital's 4 Reasons To Be Bullish On Titan Pharmaceuticals
Monday, January 26, 2015 - 6:44pm | 556Read More...Titan Pharmaceuticals, Inc. (OTCBB:TTNP) is a biomedical pharmaceutical company most known for its flagship drug, Probuphine, used to treat opioid addiction. Probuphine has proved to be effective in two clinical studies and one safety study. Titan is in the process of completing one more clinical...
-
Borders Group Names Scott Henry Executive VP, CFO
Monday, October 18, 2010 - 9:47am | 471Read More...Borders Group, Inc. (NYSE: BGP) announced it has appointed Scott Henry Executive Vice President and Chief Financial Officer, effective today. He reports to Mike Edwards, President of Borders Group, Inc. and President and CEO of Borders, Inc. Henry, 45, is a seasoned executive who brings more than...
